Found: 12
Select item for more details and to access through your institution.
Comparison of commercial dosimetric software platforms in patients treated with <sup>177</sup>Lu‐DOTATATE for peptide receptor radionuclide therapy.
- Published in:
- Medical Physics, 2020, v. 47, n. 9, p. 4602, doi. 10.1002/mp.14375
- By:
- Publication type:
- Article
225 Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 4, p. 1051, doi. 10.3390/pharmaceutics15041051
- By:
- Publication type:
- Article
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 11, p. 2247, doi. 10.3390/healthcare10112247
- By:
- Publication type:
- Article
Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-020-00737-8
- By:
- Publication type:
- Article
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [<sup>177</sup>Lu-[DOTA0, Tyr3]-octreotate.
- Published in:
- EJNMMI Research, 2018, v. 8, n. 1, p. 1, doi. 10.1186/s13550-018-0459-4
- By:
- Publication type:
- Article
Whole body planar and 3D quantitative imaging after <sup>177</sup>Lu-DOTATATE on CZT SPECT/CT device with MEHRS: collimator. First report.
- Published in:
- Hellenic Journal of Nuclear Medicine, 2021, v. 24, n. 2, p. 165
- By:
- Publication type:
- Article
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267023
- By:
- Publication type:
- Article
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 923, doi. 10.2967/jnumed.123.267023
- By:
- Publication type:
- Article
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for <sup>125</sup>I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis.
- Published in:
- Journal of Nuclear Medicine, 2009, v. 50, n. 12, p. 2033, doi. 10.2967/jnumed.109.066993
- By:
- Publication type:
- Article
Hepatobiliary Scintigraphy and Glass 90 Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver.
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 6, p. 931, doi. 10.3390/diagnostics11060931
- By:
- Publication type:
- Article
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10443-4
- By:
- Publication type:
- Article
Identification of 18 F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer.
- Published in:
- Nutrients, 2023, v. 15, n. 13, p. 3042, doi. 10.3390/nu15133042
- By:
- Publication type:
- Article